Log in or Sign up for Free to view tailored content for your specialty!
Dermatitis News
Atopic dermatitis common among children with food allergies but rarely triggered by food
Although food allergy appeared common among children with atopic dermatitis, only 3% had food-triggered atopic dermatitis, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.
Patients with atopic conditions experience transient eosinophil increases with dupilumab
Patients with asthma, chronic rhinosinusitis with nasal polyps and atopic dermatitis experienced transient increases in eosinophil counts following treatment with dupilumab, according to study results.
Log in or Sign up for Free to view tailored content for your specialty!
Dupixent shows continued, increased efficacy during long-term treatment
Long-term treatment with Dupixent was well-tolerated and showed incremental benefit with continued treatment for atopic dermatitis, consistent with results from short-term treatment.
VIDEO: ‘Future is bright’ for atopic dermatitis treatment
CLEVELAND — In this video from the Medical Dermatology Therapy Update II meeting, Amy S. Paller, MD, professor and chair of dermatology at Northwestern University, discusses new therapies on the horizon for atopic dermatitis.
Many moisturizers used in preventive emollient therapy include contact allergens
Clinicians should consider potentially harmful ingredients such as haptens when using moisturizing emollients to prevent atopic dermatitis or food allergy, according to a review published in Clinical and Translational Allergy.
Lebrikizumab maintains atopic dermatitis skin clearance for 1 year
Lebrikizumab monotherapy was efficacious in improving atopic dermatitis in 80% of patients at 1 year, according to results from two phase 3 trials announced by Eli Lilly and Company.
FDA approves Dupixent for atopic dermatitis in young children
The FDA has extended the approval of Dupixent to include children aged 6 months to 5 years with moderate to severe atopic dermatitis, Regeneron Pharmaceuticals and Sanofi announced in a press release.
Roflumilast foam shows positive topline results in seborrheic dermatitis
Seborrheic dermatitis patients treated with roflumilast foam achieved statistically significant improvement in a phase 3 trial, Arcutis Biotherapeutics announced in a press release.
VIDEO: New agents being studied for chronic urticaria
CLEVELAND — Options lessen for patients with chronic urticaria who do not respond to initial antihistamine treatment, according to James Fernandez, MD, PhD, of the department of allergy and immunology at the Cleveland Clinic.
Patients with seborrheic dermatitis dissatisfied with treatment options
Arcutis Biotherapeutics announced in a press release that only around one in four patients with seborrheic dermatitis, as well as one in 10 specialists, are satisfied with available prescription treatment options, according to a survey.
-
Headline News
Q&A: Oral injuries could be signs of abuse, neglect
September 04, 20245 min read -
Headline News
Providing menstrual products in schools ‘critical step’ to address period poverty
September 04, 20243 min read -
Headline News
Access to care, education may improve early introduction of allergens into infant diets
September 05, 20247 min read
-
Headline News
Q&A: Oral injuries could be signs of abuse, neglect
September 04, 20245 min read -
Headline News
Providing menstrual products in schools ‘critical step’ to address period poverty
September 04, 20243 min read -
Headline News
Access to care, education may improve early introduction of allergens into infant diets
September 05, 20247 min read